36 results about "Secnidazole" patented technology

The invention relates to a soluble derivate of secnidazole for curing amebic dysentery, that is secnidazole microcosmic salt or sufosuccinate monoester, wherein the compounds with above structure are chemical derivates of secnidazole which can act in the range of secnidazole. The aqueous solubility of the derivates is substantially better than secnidazole, so can be prepared to be a new type that the secnidazole can not, such as sterile powder for injecting. The invention further relates to preparation methods for secnidazole microcosmic salt or sufosuccinate monoester.

The secnidazole vaginal suppository of the present invention is composed of the following components: main ingredient secnidazole 500g, auxiliary material 36 type mixed fatty acid glyceride 2300g, made into 1000 suppositories, each weighing 2.8 grams, the 36 type mixed Fatty acid glycerides are a mixture of triglycerides, diglycerides and monoglycerides, and the melting point of type 36 mixed fatty acid glycerides is 35-37°C. The drug of the secnidazole suppository of the present invention is directly absorbed through the vagina, and will not cause damage to the heart, kidney and liver after testing. The curative effect is good, there is basically no side effect, the proportion is simple, and the use is convenient. The invention also discloses the preparation process of the secnidazole vaginal suppository at the same time.

The present invention refers to a treatment for mixed infectious diseases in the human reproductive system, wherein an association of compounds containing fluconazole and either tinidazole or secnidazole is used, the same being associated in doses lower to those commonly used therapeutically. The combination has proven to be highly efficacious and shown a good degree of tolerance.

This invention relates to secnidazole [1-(2-hydroxy group propyl)-2-methyl-5- nitro imidazole] preparation method, it belongs to chemical pharmacy technique field. 2-methyl-5-nitro imidazole and 1-chlorine-2-propyl alcohol are materials, dry acid gas is let in to dissolve solid, then heated, distilled and recover 1-chlorine-2- propanol, pH is adjusted by sig water and cooled to 0 degree centigrade. Then it is filtrated, unreacted 2-methyl-5-nitro imidazole is recovered, filtrate pH value is adjusted to alkality, and then secnidazole crude is got after filtration. Reaction temperature is 85-95 degrees cenrigrade, reaction time is 6.0-7.5 hours, mol ratio of 2-methyl-5-nitro imidazole and 1-chlorine-2-propyl alcohol is 1:3.25-5.30. Compering to existing technique, the reaction preoceudre is only one step, generating period is shortened, and operation is simplified. Reaction whole yield is improved from less than 50 percent reported from document to 56-60 percent, and material mass using is reduced, so generating cost is reduced, generating safty is also improved.

The invention discloses an interventional anti-infective water-based adhesive which comprises the following components in parts by weight: 100 parts of n-octyl a-cyanoacrylate, 10-15 parts of polymethacrylate, 4-10 parts of tetracycline, 2-6 parts of secnidazole, 0.2-0.5 part of hydroquinone and 0.05-0.2 part of sulfur dioxide. The interventional anti-infective water-based adhesive disclosed by the invention enables the human body tissues to be easy for binding in an anaerobic and solvent environment, has counter force against anaerobes, can effectively relieve the infection of the human body tissues in or after operation, and has the function of diminishing inflammation, thereby ensuring the binding effect of the human body tissues.

Embodiments described herein are directed to novel soft gelatin capsule formulations for intravaginal administration comprising secnidazole compounds and methods and uses of these pharmaceutical compositions in the treatment of bacterial vaginosis.

The invention discloses a preparation method of secnidazole, belonging to the field of medicine chemical technology. The preparation method comprises the following steps: (1) in the presence of lewis acid, reacting 2-methyl-5-nitroimidazole with epoxy propane in an organic solvent, separating an aqueous secnidazole solution from a reaction product; (2) adding hydrolysate into the aqueous secnidazole solution; after hydrolysis is completed, performing cooling and solid-liquid separation to remove unreacted 2-methyl-5-nitroimidazole; carrying out extraction, concentration, crystallization and solid-liquid separation to obtain crude secnidazole and crude mother liquor, wherein the mass ratio of hydrolate to 2-methyl-5-nitroimidazole is 5.5-8.0:1; (3) dissolving the crude secnidazole into dichloromethane, and carrying out solid-liquid separation, distillation, decoloring, crystallization and solid-liquid separation to obtain refined secnidazole and refined mother liquid. The preparation method for secnidazole has the advantages of avoiding the use of acid and alkali, lowering the cost, simplifying the process and improving the yield.

An intravenous injection of secindazole is prepared from the secnidazole as active component and the pharmacologically acceptable carrier. Its advantage is quickly taking its high curative effect.

The invention discloses a secnidazole and dexamethasone oral sustained-release medicine membrane. The secnidazole and dexamethasone oral sustained-release medicine membrane is prepared from the following raw materials in parts by weight: 0.5-1 part of secnidazole, 0.1-0.3 part of dexamethasone acetate, 2-4 parts of chitosan, 1-1.5 parts of gelatin, 4-6 parts of glycerol, 9-10 parts of ethanol, 10 parts of dilute acetic acid and about 80-100 parts of water for injection. The invention also discloses a preparation method of the secnidazole and dexamethasone oral sustained-release medicine membrane. The preparation method has the following advantages: the process is simple, the prepared secnidazole and dexamethasone oral sustained-release medicine membrane is stable in quality, convenient to use, definite in curative effect and low in manufacturing cost, has a good curative effect on treating oral inflammation and therefore is worthy of popularization.

The invention provides a Secnidazole vaginal effervescent tablet and its production method which comprises active constituent Secnidazole and effervescent tablet findings, wherein the Secnidazole amounts to 25-60% of the total weight.

This invention relates to secnidazole [1-(2-hydroxy group propyl)-2-methyl-5- nitro imidazole] preparation method, it belongs to chemical pharmacy technique field. 2-methyl-5-nitro imidazole and 1-chlorine-2-propyl alcohol are materials, dry acid gas is let in to dissolve solid, then heated, distilled and recover 1-chlorine-2- propanol, pH is adjusted by sig water and cooled to 0 degree centigrade. Then it is filtrated, unreacted 2-methyl-5-nitro imidazole is recovered, filtrate pH value is adjusted to alkality, and then secnidazole crude is got after filtration. Reaction temperature is 85-95 degrees cenrigrade, reaction time is 6.0-7.5 hours, mol ratio of 2-methyl-5-nitro imidazole and 1-chlorine-2-propyl alcohol is 1:3.25-5.30. Compering to existing technique, the reaction preoceudre is only one step, generating period is shortened, and operation is simplified. Reaction whole yield is improved from less than 50 percent reported from document to 56-60 percent, and material mass using is reduced, so generating cost is reduced, generating safty is also improved.

In alternative embodiments, provided are pharmaceutical compositions and methods for treating, ameliorating, reversing and / or preventing (acting as a prophylaxis) an Obsessive-Compulsive Disorder (OCD), with or without an accompanying autism or an autism spectrum disorder (ASD), e.g., a regressive autism. In alternative embodiments, these pharmaceutical compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, pharmaceutical compositions and methods are dosaged, formulated and dosaged as solid, liquid or aerosol preparations or formulations. In alternative embodiments, pharmaceutical compositions comprise rifaximin as the sole antibiotic, or rixafimin and other antimicrobial or antibiotic agent, for example, vancomycin, metronidazole, tinidazole, secnidazole or a combination thereof. As there are various molecular forms of rifaximins, all these are useful and used in methods and compositions as provided herein

The invention discloses the application of secnidazole in the preparation of medicines for treating and / or preventing myocardial ischemia. The invention also discloses a pharmaceutical composition for treating and / or preventing myocardial ischemia, which comprises secnidazole and pharmaceutically acceptable excipients. The results of pharmacodynamic experiments show that secnidazole has a protective effect on experimental myocardial ischemic injury, can significantly reduce the size of myocardial infarction, reduce the degree of myocardial damage, reduce serum MDA content, increase SOD active enzyme content, and can effectively resist Acute myocardial ischemia, protect the myocardium, thereby improving the symptoms of myocardial ischemia.

The present invention relates to a secnidazole vaginal expansion suppository and its preparation method and detection method; the expansion suppository comprises secnidazole, a matrix and an expansion carrier, and the drug-containing matrix of the expansion suppository contains triethanolamine oleate Can increase the dispersion uniformity of secnidazole in matrix, improve the bioavailability of suppository; Described thyme oil can improve the lubricity of suppository and the dissolution rate of active ingredient secnidazole, increase the human body's to secnidazole The absorption of azole, improve the bioavailability of suppository; Described dextran can improve the treatment of suppository vulvovaginal candidiasis, promote the healing of erosion, ulcer, improve the immunity of human body; Described dextran can also promote suppository forming, improving the stability of the suppository; the secnidazole vaginal expansion suppository is a hollow double-layer expansion suppository, and the drug-containing matrix is ​​wrapped in the matrix layer, so that the suppository of the present invention is more stable than ordinary suppositories; and the The secnidazole vaginal expansion suppository adopts six original leading technologies, which have beneficial effects such as preventing the outflow of medicinal liquid, high stability, and remarkable curative effect.

The invention relates to a pharmaceutical composition for treating gynecologic inflammations. The pharmaceutical composition comprises ciclopirox olamine, palmatine and clindamycin or secnidazole serving as active pharmaceutical ingredients, wherein a synergistic effect is achieved among the three active pharmaceutical ingredients. The preferable preparation form of the pharmaceutical composition is gel. The product is uniform, fine and smooth in texture and appropriate in thickness. The pharmaceutical composition can be used for effectively treating mixed infectious diseases, particularly mixed infective vaginitis.